This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Strategic Collaborations Aid QGEN Stock Amid Competition
by Zacks Equity Research
QIAGEN invests heavily in research and development to support internal growth, including the menu expansion of its key platforms.
NEOG Stock Gains Following the Launch of Its New MDA2QSAL96 Kit
by Zacks Equity Research
Neogen launches the new Molecular Detection Assay 2 - Quantitative Salmonella (MDA2QSAL96) to deliver consistency and sensitivity with an easy-to-use workflow that saves time and resources.
Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now
by Zacks Equity Research
BIO's robust performance of the ddPCR platform and clinical diagnostics momentum bodes well for investors.
Align Technology Shares Hurt by Macro Issues, Decline in ASPs
by Zacks Equity Research
ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This resulted in a decline in the company's revenues.
Reasons to Retain Envista Stock in Your Portfolio for Now
by Zacks Equity Research
NVST's strong focus on international market expansion appears promising. Yet, a leveraged balance sheet is worrisome.
HSIC Stock Might Rise Following the Acquisition of Acentus
by Zacks Equity Research
Henry Schein completes the acquisition of Acentus, which expands the former's Home Solution business.
Should Edwards Lifesciences Stock Stay in Your Portfolio Now?
by Zacks Equity Research
EW stock is on investors' radar courtesy to the promising structural heart opportunities post the divestment of the Critical Care arm.
PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU
by Zacks Equity Research
Insulet announces the launch of Omnipod 5 in five more countries in Europe, Italy, Denmark, Finland, Norway and Sweden.
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
by Zacks Equity Research
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
TECH Stock Might Rise From the Expansion of Designer Protein Portfolio
by Zacks Equity Research
Bio-Techne launches AI-engineered designer proteins to advance cell therapy and regenerative medicine.
GMED Stock Rides on NuVasive Synergy Benefits Amid Macro Issues
by Zacks Equity Research
Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
MYGN Stock Gains Following Collaboration With Hannah Storm
by Zacks Equity Research
Myriad Genetics enters into an agreement with Hannah Storm, who will be the Myriad Genetics Breast Cancer Risk Assessment Program ambassador.
Expanding Global Network, Vaccine Sales Support PAHC Stock
by Zacks Equity Research
Phibro Animal Health is focusing on new developments along with incremental registrations and growing volumes of existing vaccine technologies.
BSX Stock Rises Following Bolt Medical Acquisition Deal Announcement
by Zacks Equity Research
Boston Scientific inks a new agreement to acquire Bolt Medical, developer of Bolt IVL, for approximately $443 million.
Should Exact Sciences Stock Stay in Your Portfolio Right Now?
by Zacks Equity Research
EXAS' solid focus on expanding its lead Cologuard test and advancing new solutions bodes well for investors.
QGEN Stock Might Rise Following Partnership With Genomics England
by Zacks Equity Research
QIAGEN partners with Genomics England to support the United Kingdom's initiative to sequence the genomes of 100,000 newborns with expert-curated genomic content.
Endoscopy Sales Growth to Support BSX Stock Amid Fierce Competition
by Zacks Equity Research
Boston Scientific successfully continues its expansion of operations across different geographies outside the United States.
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
HOLX Stock Gains Following the Acquisition of Gynesonics
by Zacks Equity Research
Hologic completes the acquisition of Gynesonics, developer of the Sonata System, for approximately $350 million.
Reasons to Add Penumbra Stock to Your Portfolio Now
by Zacks Equity Research
PEN stays on investors' radars due to its strong Thrombectomy business and international growth plans.
Should National Vision Stock Be in Your Portfolio Right Now?
by Zacks Equity Research
Investors are optimistic about EYE stock, courtesy of its share gain in the Owned and Host segments.
Veracyte Gains 44% in a Year: What's Driving the Stock?
by Zacks Equity Research
VCYT is gaining shares due to the strength of its Afirma and Decipher tests.
Macroeconomic Woes, FX Headwind Drag NEOG Stock Down
by Zacks Equity Research
NEOG faces intense competition due to the development of new technologies by competitors, which could affect the marketability and profitability of its products.
Phibro Animal Health Gains 83% in a Year: What's Driving the Stock?
by Zacks Equity Research
PAHC shares gain owing to the remarkable performance of the Animal Health business and potential in the emerging markets.
Should You Retain Labcorp Stock in Your Portfolio Right Now?
by Zacks Equity Research
Investors are increasingly optimistic about LH due to its focus on high-growth areas and strategic partnerships.